查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
阵发性睡眠性血红蛋白尿药物市场，按治疗、按药物、按给药途径、最终用户、按国家和地区划分 - 2023-2030 年行业分析、市场规模、市场份额和预测
市场调查报告书
商品编码
1351435

阵发性睡眠性血红蛋白尿药物市场，按治疗、按药物、按给药途径、最终用户、按国家和地区划分 - 2023-2030 年行业分析、市场规模、市场份额和预测

Paroxysmal Nocturnal Hemoglobinuria Drug Market, By Treatment, By Drugs, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 281 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年阵发性睡眠性血红素尿症药物市场规模为34.702亿美元，2023年至2030年复合年增长率为13.8%。

阵发性睡眠性血红素尿药市场 - 市场动态：

  • 不断增长的监管批准和研发推动市场成长
  • 全球阵发性睡眠性血红蛋白尿药物市场的发展在很大程度上取决于欧洲药品管理局（EMA）、美国食品药物管理局（FDA）以及其他国际监管机构等组织的监管批准。 Eculizumab和ravulizumab的市场占有率和患者可近性受益于它们的批准，奠定了坚实的基础。此外，尝试发现新的治疗替代方案并增强现有疗法是 PNH 领域持续研究和开发的主要目标。这包括研究组合药物、开发创新的标靶疗法和替代给药技术。这些发展和突破有助于PNH药品产业的扩大和发展。

阵发性睡眠性血红蛋白尿药物市场 - 主要见解：

  • 根据我们的研究分析师分享的分析，全球阵发性睡眠性血红蛋白尿药物市场预计在预测期内（2023-2030）每年将以 13.8% 左右的复合年增长率增长
  • 由于监管部门批准的不断增加，阵发性睡眠性血红蛋白尿药物产业预计将以显着的速度成长
  • 根据治疗，输血领域预计将在预测期内主导市场
  • 从地区来看，预计北美将在预测期内主导市场

阵发性睡眠性血红素尿症药物市场-細項分析：

  • 全球阵发性睡眠性血红蛋白尿药物市场根据治疗、药物、给药途径、最终用户和地区进行细分。
  • 根据治疗，市场分为药物、补充剂、输血和骨髓移植。预计输血领域将在预测期内主导市场。输血是可能有助于减轻贫血症状的疗法之一。 PNH 会引起包括血栓形成在内的严重不良影响，如果不及时治疗可能会致命。 PNH 患者经常需要输血来治疗贫血症状，因为在输血过程中，患者会接受捐赠者的血液或血液製品。从而推动市场成长。

阵发性睡眠性血红素尿症药物市场-地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。这些区域根据开展业务的国家进一步划分。预计北美将在预测期内主导市场。开发和推广 PNH 标靶治疗的主要製药公司主导了该地区的 PNH 药物市场。像 Alexion Pharmaceuticals（现在是阿斯特捷利康的一个部门）和药物 eculizumab（以 Soliris 名称销售）这样的公司对市场环境产生了重大影响。此外，PNH 药物的批准和供应很大程度上受到北美（尤其是美国）监管环境的影响。治疗PNH 的标靶药物，如依库珠单抗(eculizumab) 和拉维珠单抗(ravulizumab)（以Ultomiris 品牌上市）已获得美国食品药物管理局(FDA) 的批准，有助于其在该领域的广泛使用。

阵发性睡眠性血红素尿药市场-竞争格局：

全球深水碳氢化合物勘探市场的领先公司正在加强研发力度，以实现产品多元化。此外，这些市场参与者利用策略联盟和合作伙伴关係来促进成长。市场上的主要参与者包括 Ra Pharmaceuticals Inc、CinnaGen Co、Akari Therapeutics Plc、Alexion Pharmaceuticals Inc、Apellis Pharmaceuticals、Abbott、NorthStar Rx LLC、Alnylam Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Novartis AG、Regeneron Pharmaceuticals Inc、F.offmann-La Roche Ltd、Novartis AG、Regeneron Pharmaceuticals Inc. BIOCAD、Samsung Bioepis、Amyndas Pharmaceuticals、Teva Pharmaceutical Industries Ltd.、LGM Pharma.、Lannett、Achillion Pharmaceuticals Inc 与Amgen Inc.

最近的发展：

据中外製药称，2023 年9 月，美国食品和药物管理局(FDA) 批准了crovalimab 的生物製剂许可申请(BLA)，crovalimab 是一种实验性全新抗C5 循环单株抗体，用于治疗阵发性睡眠性血红蛋白尿症(PNH) 此次接受是基于关键的III 期COMMODORE 2 研究结果，该研究结果表明Crovalimab 有效控制了疾病，并且在PNH 患者中具有良好的耐受性。1 Crovalimab 的持续获益风险概况如III 期COMMODORE 1 研究中所示研究结果为此应用提供了额外的证据。

目录

第 1 章：阵发性睡眠性血红素尿药市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 阵发性睡眠性血红素尿药市场片段（依治疗）
    • 阵发性睡眠性血红素尿药市场片段（依药物）
    • 阵发性睡眠性血红素尿药市场片段（依给药途径）
    • 最终用户的阵发性睡眠性血红蛋白尿药物市场片段
    • 阵发性睡眠性血红素尿药市场片段（依国家/地区）
    • 按地区分類的阵发性睡眠性血红素尿药市场片段
  • 竞争洞察

第 3 章：阵发性睡眠性血红素尿药主要市场趋势

  • 阵发性睡眠性血红素尿药市场驱动因素
    • 市场驱动因素的影响分析
  • 阵发性睡眠性血红素尿药市场限制
    • 市场限制影响分析
  • 阵发性睡眠性血红素尿药市场机会
  • 阵发性睡眠性血红素尿药市场未来趋势

第 4 章：阵发性睡眠性血红素尿药物工业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：阵发性睡眠性血红素尿药市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：阵发性睡眠性血红素尿药市场格局

  • 2022 年阵发性睡眠性血红素尿药市场份额分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：阵发性睡眠性血红素尿药市场 - 依治疗分类

  • 概述
    • 按处理方式分類的细分市场占有率分析
    • 药物
    • 补充品
    • 输血
    • 骨髓移植

第 8 章：阵发性睡眠性血红素尿药市场 - 依药物分类

  • 概述
    • 按药品分類的细分市场占有率分析
    • 依库珠单抗
    • 拉维利珠单抗
    • 其他的

第 9 章：阵发性睡眠性血红素尿药市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 注射用

第 10 章：阵发性睡眠性血红蛋白尿药物市场 - 依最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 居家护理
    • 专科诊所
    • 其他的

第 11 章：阵发性睡眠性血红素尿药市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 阵发性睡眠性血红素尿症药物北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模与预测（以不同处理方式）
    • 北美市场规模和预测（按药品）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲阵发性睡眠性血红素尿症药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按处理方式）
    • 欧洲市场规模与预测（按药品）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区阵发性睡眠性血红素尿症药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（以不同处理方式）
    • 亚太地区药品市场规模及预测
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲阵发性睡眠性血红素尿症药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（以不同处理方式）
    • 拉丁美洲市场规模与预测（按药品）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲阵发性睡眠性血红素尿药主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东及非洲市场规模及预测（依不同处理方式）
    • 中东和非洲市场规模及预测（按药品）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 阵发性睡眠性血红素尿药物产业

  • 竞争仪表板
  • 公司简介
    • Ra Pharmaceuticals Inc
    • CinnaGen Co
    • Akari Therapeutics Plc
    • Alexion Pharmaceuticals Inc
    • Apellis Pharmaceuticals
    • Abbott
    • NorthStar Rx LLC
    • Alnylam Pharmaceuticals Inc
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • BIOCAD
    • Samsung Bioepis
    • Amyndas Pharmaceuticals
    • Teva Pharmaceutical Industries Ltd.
    • LGM Pharma.
    • Lannett
    • Achillion Pharmaceuticals Inc
    • Amgen Inc

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1670

REPORT HIGHLIGHT

Paroxysmal Nocturnal Hemoglobinuria Drug Market size was valued at USD 3,470.2 Million in 2022, expanding at a CAGR of 13.8% from 2023 to 2030.

Red blood cells are destroyed (hemolyzed) and aberrant red blood cells are present in the circulation in paroxysmal nocturnal hemoglobinuria (PNH), an uncommon and possibly fatal blood condition. It results from excessive activation of the complement system, a component of the immune system in charge of removing foreign substances in the body, which is brought on by a genetic mutation that affects the proteins on the surface of red blood cells.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Market Dynamics:

  • Growing regulatory approvals and R&D drives market growth
  • The developments of the worldwide paroxysmal nocturnal hemoglobinuria medicine market heavily depend on regulatory approvals from organizations like the European Medicines Agency (EMA), the U.S. Food and medicine Administration (FDA), and other international regulatory agencies. Eculizumab and ravulizumab's market presence and patient accessibility have benefited from their approval, which has laid a solid basis. Additionally, attempts to discover novel therapy alternatives and enhance existing therapies are the main goals of continuing research and development in the field of PNH. This includes investigating combination medicines, developing innovative targeted therapeutics, and alternate administration techniques. These developments and breakthroughs help the PNH drugs industry expand and develop.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Paroxysmal Nocturnal Hemoglobinuria Drug market is estimated to grow annually at a CAGR of around 13.8% over the forecast period (2023-2030)
  • The Paroxysmal Nocturnal Hemoglobinuria Drug industry is projected to grow at a significant rate owing to the growing regulatory approvals
  • Based on treatment, the blood transfusion segment is expected to dominate the market over the forecast period
  • Based on region, North America is expected to dominate the market over the forecast period

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Segmentation Analysis:

  • The Global Paroxysmal Nocturnal Hemoglobinuria Drug Market is segmented based on treatment, drugs, route of administration, end user, and Region.
  • Based on treatment, the market is bifurcated into medication, supplements, blood transfusion, and bone marrow transplants. The blood transfusion segment is expected to dominate the market over the forecast period. Blood transfusion is one of the therapies that might help to lessen the symptoms of anemia. PNH causes major adverse effects including thrombosis and can be deadly if left untreated. PNH patients frequently require blood transfusions to treat their anemic symptoms because, during a transfusion, the patients receive blood or blood products from a donor. Thus, driving the market growth.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. Major pharmaceutical firms that create and promote targeted therapy for PNH dominate the region's PNH medication market. Companies like Alexion Pharmaceuticals, which is now a division of AstraZeneca, and the medicine eculizumab (marketed under the name Soliris), have had a substantial impact on the market environment. Additionally, the approval and availability of PNH medications are greatly influenced by the regulatory climate in North America, notably the United States. Targeted treatments for the treatment of PNH, such as eculizumab and ravulizumab (marketed under the brand Ultomiris), have been approved by the U.S. Food and Drug Administration (FDA), which has contributed to their extensive usage in the area.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Competitive Landscape:

Leading companies in the worldwide Deepwater Hydrocarbon Exploration market are stepping up their R&D efforts to diversify their product offerings. Additionally, these market participants use strategic alliances and partnerships that promote growth. The key players operating in the market include Ra Pharmaceuticals Inc, CinnaGen Co, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Apellis Pharmaceuticals, Abbott, NorthStar Rx LLC, Alnylam Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, BIOCAD, Samsung Bioepis, Amyndas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, Achillion Pharmaceuticals Inc and Amgen Inc.

Recent Developments:

In September 2023, the US Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for crovalimab, an experimental, brand-new anti-C5 recycling monoclonal antibody, to treat paroxysmal nocturnal hemoglobinuria (PNH), according to Chugai Pharmaceutical Co., Ltd. The acceptance was based on the key phase III COMMODORE 2 study's findings, which showed that crovalimab effectively controlled illness and was well tolerated in PNH patients.1 Crovalimab's constant benefit-risk profile as seen in the phase III COMMODORE 1 study's findings provided additional evidence for the application.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET KEY PLAYERS

  • Ra Pharmaceuticals Inc
  • CinnaGen Co
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Apellis Pharmaceuticals
  • Abbott
  • NorthStar Rx LLC
  • Alnylam Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • BIOCAD
  • Samsung Bioepis
  • Amyndas Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • LGM Pharma.
  • Lannett
  • Achillion Pharmaceuticals Inc
  • Amgen Inc

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY TREATMENT

  • Medication
  • Supplements
  • Blood Transfusion
  • Bone Marrow Transplant

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY DRUGS

  • Eculizumab
  • Ravulizumab
  • Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

  • Oral
  • Parenteral

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY END USER

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Treatment
    • 2.1.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Drugs
    • 2.1.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Route of Administration
    • 2.1.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by End User
    • 2.1.5. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Country
    • 2.1.6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Paroxysmal Nocturnal Hemoglobinuria Drug Key Market Trends

  • 3.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Opportunities
  • 3.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Future Trends

4. Paroxysmal Nocturnal Hemoglobinuria Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Paroxysmal Nocturnal Hemoglobinuria Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Landscape

  • 6.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Treatment

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
    • 7.1.2. Medication
    • 7.1.3. Supplements
    • 7.1.4. Blood Transfusion
    • 7.1.5. Bone Marrow Transplant

8. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Drugs

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drugs, 2022 & 2030 (%)
    • 8.1.2. Eculizumab
    • 8.1.3. Ravulizumab
    • 8.1.4. Others

9. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
    • 9.1.2. Oral
    • 9.1.3. Parenteral

10. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Homecare
    • 10.1.4. Specialty Clinics
    • 10.1.5. Others

11. Paroxysmal Nocturnal Hemoglobinuria Drug Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

12. Key Vendor Analysis- Paroxysmal Nocturnal Hemoglobinuria Drug Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Ra Pharmaceuticals Inc
    • 12.2.2. CinnaGen Co
    • 12.2.3. Akari Therapeutics Plc
    • 12.2.4. Alexion Pharmaceuticals Inc
    • 12.2.5. Apellis Pharmaceuticals
    • 12.2.6. Abbott
    • 12.2.7. NorthStar Rx LLC
    • 12.2.8. Alnylam Pharmaceuticals Inc
    • 12.2.9. F. Hoffmann-La Roche Ltd
    • 12.2.10. Novartis AG
    • 12.2.11. Regeneron Pharmaceuticals Inc
    • 12.2.12. BIOCAD
    • 12.2.13. Samsung Bioepis
    • 12.2.14. Amyndas Pharmaceuticals
    • 12.2.15. Teva Pharmaceutical Industries Ltd.
    • 12.2.16. LGM Pharma.
    • 12.2.17. Lannett
    • 12.2.18. Achillion Pharmaceuticals Inc
    • 12.2.19. Amgen Inc

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Treatment Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Drugs Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drugs
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Route of Administration Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: End User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Region 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)